287 related articles for article (PubMed ID: 21144773)
1. Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results.
Navarro-González JF; Muros M; Mora-Fernández C; Herrera H; Meneses B; García J
J Diabetes Complications; 2011; 25(5):314-9. PubMed ID: 21144773
[TBL] [Abstract][Full Text] [Related]
2. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
Navarro JF; Mora C; Muros M; García J
J Am Soc Nephrol; 2005 Jul; 16(7):2119-26. PubMed ID: 15917336
[TBL] [Abstract][Full Text] [Related]
3. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.
Navarro-González JF; Mora-Fernández C; Muros de Fuentes M; Chahin J; Méndez ML; Gallego E; Macía M; del Castillo N; Rivero A; Getino MA; García P; Jarque A; García J
J Am Soc Nephrol; 2015 Jan; 26(1):220-9. PubMed ID: 24970885
[TBL] [Abstract][Full Text] [Related]
4. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
5. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
Onuigbo MA; Onuigbo NT
QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
[TBL] [Abstract][Full Text] [Related]
6. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
Pisoni R; Faraone R; Ruggenent P; Remuzzi G
J Nephrol; 2002; 15(4):428-30. PubMed ID: 12243375
[TBL] [Abstract][Full Text] [Related]
8. Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
Ivory SE; Packham DK; Reutens AT; Wolfe R; Rohde RD; Lewis J; Atkins RC;
Nephrology (Carlton); 2013 Jul; 18(7):516-24. PubMed ID: 23506627
[TBL] [Abstract][Full Text] [Related]
9. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
10. High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria.
Ito H; Takeuchi Y; Ishida H; Antoku S; Abe M; Mifune M; Togane M
Nephrol Dial Transplant; 2010 Apr; 25(4):1161-7. PubMed ID: 19892756
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
Schjoedt KJ; Lajer M; Andersen S; Tarnow L; Rossing P; Parving HH
Scand J Clin Lab Invest; 2006; 66(3):173-80. PubMed ID: 16714246
[TBL] [Abstract][Full Text] [Related]
12. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
Navarro JF; Milena FJ; Mora C; León C; García J
Am J Nephrol; 2006; 26(6):562-70. PubMed ID: 17167242
[TBL] [Abstract][Full Text] [Related]
13. Diabetic nephropathy.
Ritz E
Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):481-90. PubMed ID: 17186681
[TBL] [Abstract][Full Text] [Related]
14. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Perkins RM; Aboudara MC; Uy AL; Olson SW; Cushner HM; Yuan CM
Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
[TBL] [Abstract][Full Text] [Related]
15. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
[TBL] [Abstract][Full Text] [Related]
16. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
17. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
Lin SL; Chen YM; Chiang WC; Wu KD; Tsai TJ
Am J Kidney Dis; 2008 Sep; 52(3):464-74. PubMed ID: 18617301
[TBL] [Abstract][Full Text] [Related]
18. Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes.
Schievink B; Kröpelin T; Mulder S; Parving HH; Remuzzi G; Dwyer J; Vemer P; de Zeeuw D; Lambers Heerspink HJ
Diabetes Obes Metab; 2016 Jan; 18(1):64-71. PubMed ID: 26434564
[TBL] [Abstract][Full Text] [Related]
19. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design.
Shikata K; Haneda M; Koya D; Suzuki Y; Tomino Y; Yamada K; Maeda S; Kawakami N; Uzu T; Nishimura M; Sato C; Ogawa D; Makino H;
Diabetes Res Clin Pract; 2010 Feb; 87(2):228-32. PubMed ID: 19889469
[TBL] [Abstract][Full Text] [Related]
20. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial.
Goicoechea M; García de Vinuesa S; Quiroga B; Verdalles U; Barraca D; Yuste C; Panizo N; Verde E; Muñoz MA; Luño J
J Nephrol; 2012; 25(6):969-75. PubMed ID: 22241639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
